Fragment-Based Lead Discovery
Charles River has extensive capabilities in fragment-based drug discovery, offering access to expertise in screening, structural biology, as well as computational and medicinal chemistry.
Our range of fragment libraries and orthogonal fragment screening technologies allows us to customize a fragment-based lead discovery solution to a wide array of target types.
Our fragment-based drug discovery (FBDD) platform provides access to:
|Orthogonal Screening Technologies||Technologies include thermal shift assay, surface plasmon resonance (SPR) using Biacore™ instrumentation, isothermal titration calorimetry (ITC), NMR, high-concentration biochemical assay and X-ray crystallography|
|Structural Biology||Experience in the development of structure routes to support FBDD; in-house X-ray facility and Crystal Bank of structures|
|1,500 member core library, 500 member kinase focused set and 500 member 19F labelled set, all designed for fragment screening and rapid FBDD optimization of hits|
|Computational Chemistry||Proprietary fragment hit expansion techniques and fragment shape-based analysis tools|
|Medicinal Chemistry||Expertise in structure-based drug discovery and fragment hit optimization|